Previous 10 | Next 10 |
Gainers: CDLX +20.8% . TWOU +14.6% . DDOG +14.2% . VRAY +9.3% . NBRV +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...
NextCure (NASDAQ: NXTC ) is 7.8% lower after hours after filing to offer 3.2M shares of common stock. More news on: NextCure, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public...
NextCure (NASDAQ: NXTC ): Q3 GAAP EPS of -$0.37 misses by $0.02 . More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2019...
Major benchmarks finished mixed on generally quiet day on Wall Street. The Dow Jones Industrial Average (DJINDICES: ^DJI) eked out a gain while the S&P 500 (SNPINDEX: ^GSPC) posted a modest loss. The industrial and real estate sectors rose, with home construction ...
Gainers: Taronis Technologies (NASDAQ: TRNX ) +43% . More news on: Taronis Technologies, Inc., Carbonite, Inc., Jounce Therapeutics, Inc., Stocks on the move, Read more ...
Lipocine (NASDAQ: LPCN ) -77% after FDA rejects second Tlando application. More news on: Lipocine Inc., NextCure, Inc., Foamix Pharmaceuticals Ltd., Stocks on the move, Read more ...
Thinly traded NextCure (NASDAQ: NXTC ) is down 53% premarket on modest volume on the heels of updated results from the first part of its Phase 1/2 clinical tria l evaluating NC318, a Siglec-15 (S15)-targeting monoclonal antibody, in patients with solid tumors. The data were pr...
Eight small companies and four SPACs entered the public market this past week. Continuing a 4Q trend, all eight deals priced below the midpoint; the average IPO priced 11% below the midpoint, traded up 1% on its first day, and finished the week up 3%. Four of the eight had significant insider ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...